The S&P closed 20% below its all-time high set in October, making it the last of the three major U.S. stock indexes to fall into a bear market. What's the "Word on the Street?"   Read More

Following are the day’s biggest winners and losers. Find out why shares of Chesapeake Energy and AstraZeneca popped while Circuit City and Western Union dropped.   Read More

I'm thinkin' those two drug giants are champin' at the bit for the docs to get McCain off generic Zocor and onto Lipitor or Crestor. On recent conference calls, some PFE officials have said they think a lot of patients who've had a similar experience to McCain's will eventually come back around to Lipitor.    Read More

If sales of Amgen's anemia drugs hadn't fallen so much last year, the American biotechnology industry probably would have turned its first profit in history. That's one of the main conclusions of Ernst & Young's comprehensive annual report on the sector that came out today.    Read More

Following are the day’s biggest winners and losers. Find out why shares of Nike and BHP Billiton popped while Whole Foods and American Apparel dropped.   Read More

The irreverent producers of "Squawk on the Street" who are stationed in the pod next to mine here at CNBC like to call it "Pharmapalooza." They're referring to weeks like the one coming up when nearly every big drug company reports earnings.    Read More

CNBC and other media outlets have done a significant amount of reporting on cardiologists' reaction to the Vytorin/Zetia study and the effect the ACC panel's opinion might have on the heart doctors' prescription writing.    Read More

Cramer makes the call on viewers' favorite stocks.   Read More

Shares of Merck and Schering-Plough are both under the weather Monday after a study said their Vytorin cholesterol drug isn't any better than a generic. Who wins and who loses?   Read More

Who’s the winner and loser in drug stocks today? Schering-Plough down 25 percent (!) and Merck down 16 percent pre-open on a study that showed that the companies cholesterol lowering drugs Vytorin and Zetia were not more effective than less expensive drugs.    Read More